TP53 and diffuse large B-cell lymphoma: Based on the data from the training cohort and validation cohort, we established and validated a nomogram that incorporated pretreatment TMTV, SDmax, and TP53 status to predict PFS of DLBCL patients, showing higher predictive performance than the clinical risk scores.